ADITEC
Advanced Immunization Technologies
| Coordinatore | SCLAVO VACCINES ASSOCIATION
Organization address
address: PIAZZA LA LIZZA 7 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 40˙876˙617 € |
| EC contributo | 29˙980˙670 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2016-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SCLAVO VACCINES ASSOCIATION
Organization address
address: PIAZZA LA LIZZA 7 contact info |
IT (SIENA) | coordinator | 5˙052˙094.10 |
| 2 |
UNIVERSITY OF SURREY
Organization address
address: Stag Hill contact info |
UK (GUILDFORD) | participant | 1˙331˙163.00 |
| 3 |
UNIVERSITA' DEGLI STUDI DI SIENA
Organization address
address: VIA BANCHI DI SOTTO 55 contact info |
IT (SIENA) | participant | 1˙314˙800.00 |
| 4 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 1˙225˙900.00 |
| 5 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 1˙098˙248.40 |
| 6 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 1˙026˙250.00 |
| 7 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 1˙020˙000.00 |
| 8 |
GLAXOSMITHKLINE VACCINES SRL
Organization address
address: Via Fiorentina 1 contact info |
IT (SIENA) | participant | 973˙185.00 |
| 9 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 973˙050.00 |
| 10 |
WORLD HEALTH ORGANIZATION.
Organization address
address: Avenue Appia 20 contact info |
CH (GENEVE) | participant | 950˙000.00 |
| 11 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 920˙000.00 |
| 12 |
SCLAVO BEHRING VACCINES INSTITUTE FOR GLOBAL HEALTH S.R.L.
Organization address
address: VIA FIORENTINA 1 contact info |
IT (Siena) | participant | 918˙254.00 |
| 13 |
EMORY UNIVERSITY NON PROFIT CORP
Organization address
address: Clifton Road, NE, 4th Floor 1599 contact info |
US (Atlanta) | participant | 850˙000.00 |
| 14 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 830˙000.00 |
| 15 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 757˙672.50 |
| 16 |
MEDICINE IN NEED (MEND) FRANCE ASSOCIATION
Organization address
address: RUE DU BOULOI 4 contact info |
FR (PARIS) | participant | 723˙075.00 |
| 17 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 570˙000.00 |
| 18 |
REITHERA SRL
Organization address
address: VIA GAETANO SALVATORE 486 contact info |
IT (Napoli) | participant | 567˙000.00 |
| 19 |
UNIVERSITAET INNSBRUCK
Organization address
address: INNRAIN 52 contact info |
AT (INNSBRUCK) | participant | 566˙984.57 |
| 20 |
SEATTLE BIOMEDICAL RESEARCH INSTITUTE NON PROFIT CORPORATION
Organization address
address: WESTLAKE AVENUE 307 contact info |
US (SEATTLE WA) | participant | 522˙934.00 |
| 21 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 502˙985.00 |
| 22 |
ISTITUTO SUPERIORE DI SANITA
Organization address
address: Viale Regina Elena 299 contact info |
IT (ROMA) | participant | 495˙000.00 |
| 23 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 480˙000.00 |
| 24 |
FONDAZIONE HUMANITAS PER LA RICERCA
Organization address
address: Via Manzoni 56 contact info |
IT (ROZZANO) | participant | 480˙000.00 |
| 25 |
FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA
Organization address
address: Via Vincenzo Vela 6 contact info |
CH (BELLINZONA) | participant | 480˙000.00 |
| 26 |
UNIVERSITEIT UTRECHT
Organization address
address: Heidelberglaan 8 contact info |
NL (UTRECHT) | participant | 480˙000.00 |
| 27 |
Infectious Disease Research Institute
Organization address
address: EASTLAKE AVE E 1616 STE 400 contact info |
US (SEATTLE WA) | participant | 471˙000.00 |
| 28 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 460˙000.00 |
| 29 |
Hookipa Biotech AG
Organization address
address: HELMUT QUALTINGER GASSE 2 contact info |
AT (Wien) | participant | 435˙000.00 |
| 30 |
CROSSBETA BIOSCIENCES BV
Organization address
address: PADUALAAN 8 contact info |
NL (UTRECHT) | participant | 339˙600.00 |
| 31 |
ABERA BIOSCIENCE AB
Organization address
address: STUREPLAN 15 contact info |
SE (STOCKHOLM) | participant | 314˙937.60 |
| 32 |
VACCIBODY AS
Organization address
address: GAUSTADALLEEN 21 contact info |
NO (OSLO) | participant | 292˙438.00 |
| 33 |
DUOTOL AB
Organization address
address: KORVETTGATAN 1D contact info |
SE (VASTRA FROLUNDA) | participant | 290˙000.00 |
| 34 |
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Organization address
address: VIA FIORENTINA 151 contact info |
IT (SIENA) | participant | 265˙000.00 |
| 35 |
PEVION BIOTECH AG
Organization address
address: WORBLENTALSTRASSE 32 contact info |
CH (ITTIGEN) | participant | 262˙541.00 |
| 36 |
VALNEVA AUSTRIA GMBH
Organization address
address: CAMPUS VIENNA BIOCENTER 3 contact info |
AT (WIEN) | participant | 236˙756.52 |
| 37 |
SIGMOID PHARMA LIMITED
Organization address
address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY contact info |
IE (DUBLIN) | participant | 208˙080.00 |
| 38 |
Department of Health
Organization address
address: Quarry House, Quarry Hill contact info |
UK (Leeds) | participant | 203˙040.19 |
| 39 |
MICROBIOTEC srl
Organization address
address: Via delle Vigne 12 contact info |
IT (Monteriggioni (SI)) | participant | 202˙800.00 |
| 40 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 200˙400.00 |
| 41 |
STICHTING TUBERCULOSIS VACCINE INITIATIVE
Organization address
address: Runderweg 6 contact info |
NL (LELYSTAD) | participant | 193˙000.00 |
| 42 |
BIONEEDLE TECHNOLOGIES GROUP BV
Organization address
address: GARONNELAAN 10 contact info |
NL (EINDHOVEN) | participant | 154˙200.00 |
| 43 |
VISMEDERI SRL
Organization address
address: VIA FIORENTINA 1 contact info |
IT (SIENA SI) | participant | 150˙000.00 |
| 44 |
XBRANE BIOSCIENCE AB
Organization address
address: STUREPLAN 15 contact info |
SE (STOCKHOLM) | participant | 117˙062.40 |
| 45 |
OESTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN
Organization address
address: DR. IGNAZ SEIPEL-PLATZ 2 contact info |
AT (WIEN) | participant | 71˙015.43 |
| 46 |
Intercell AG
Organization address
address: Campus Vienna Biocenter 3 contact info |
AT (Vienna) | participant | 4˙243.48 |
| 47 |
HEALTH PROTECTION AGENCY HPA
Organization address
address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 contact info |
UK (LONDON) | participant | 959.81 |
| 48 |
ARENAVAX AG
Organization address
address: WAGISTRASSE 21 contact info |
CH (SCHLIEREN) | participant | 0.00 |
| 49 |
GlaxoSmithKline Biologicals
Organization address
address: Rue de l'Institut 89 contact info |
BE (Rixensart) | participant | 0.00 |
| 50 |
HOOKIPA BIOTECH GMBH
Organization address
address: JULIUS RAAB PLATZ 4 contact info |
AT (WIEN) | participant | 0.00 |
| 51 |
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
Organization address
address: Cranmer Terrace contact info |
UK (LONDON) | participant | 0.00 |
| 52 |
VALNEVA SE
Organization address
address: RUE SAINT JEAN DE DIEU 70 contact info |
FR (LYON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise. A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous prime–boost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. ADITEC scientists and institutions are part of the “Sclavo Vaccines Association” (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.
Introduzione (Teaser)
A collaborative European research programme is working on novel and powerful immunisation technologies towards the development of next-generation human vaccines.
Descrizione progetto (Article)
Vaccination is a powerful means of tackling disease by artificially inducing immunity against pathogens. In the past, vaccine development has relied solely on empirical approaches. However, advances in science and technology promise to transform vaccinology into a dynamic field.
In this context, the EU-funded http://www.aditecproject.eu/ (ADITEC) (Advanced immunization technologies) project has brought together experts in the field of immunology and vaccine development. The aim is to produce the knowledge necessary to develop novel and powerful immunisation technologies for producing effective adaptable human vaccines.
The consortium is following a systems biology approach to test a broad panel of adjuvants, live vaccine vectors, formulations and delivery devices. The focus is on vaccines against influenza H1, M. tuberculosis H56 and Chlamydia MOMP. So far, apart from classical adjuvants, the consortium has also designed second generation adjuvants. They are in the process of identifying the molecular signatures that correlate with and predict adaptive and innate responses to vaccination.
Scientists are performing pre-clinical, clinical and population-based studies to evaluate the efficacy of novel immunisation technologies and identify the optimal strategies for specific target groups. They have already analysed how T cell-priming is elicited by different routes of vaccination in rodent models. In addition, they are assessing the impact of host factors such as age, gender, genetics and pathologies in immunisation outcome. So far, the pre-clinical work has resulted in new vaccine candidates which have been advanced in a phase I clinical trial.
Collectively, the activities of the ADITEC project respond fully to the urgent need to develop advanced immunisation technologies for safer and better vaccines. Furthermore, they will generate important new knowledge on human immune responses associated with these improved vaccines and will enable informed decisions on their implementation.